Jennewein Biotechnologie expands into Chinese marketJennewein Biotechnologie and Asia’s largest dairy company Yili Group have joined forces to develop an innovative infant formula tailored to the Chinese market. more ➔
Medicxi put €40m into two Sosei spin off companiesSosei Group Corporation has spun out two programmes of its neurology pipeline into two newly created companies funded by venture fund Medicxi. more ➔
EMA greenlights two orphan drugs and two biosimilarsEMA’s human medicines committee (CHMP) recommended six medicines for approval at its January 2019 meeting. more ➔
Hitachi expands European reach in cell and gene therapyHitachi Chemical Co. Ltd. is set to takeover cell and gene therapy CDMO apceth Biopharma GmbH to get a foothold in Europe, the second largest market for advanced therapies after the US. more ➔
Dewpoint Therapeutics kicks off with $60m financingDewpoint Therapeutics has attracted interested of investors with a completely new approach that might cure a huge array of devasting diseases. more ➔
IPO: Marinomed sets offer priceMarinomed has set the offer price for its IPO at Vienna Stock Exchange at the lower limit of €75 per new share. more ➔
Novozymes partners with Carbios subsidiary CarbioliceNovozymes has entered into a partnership with French Carbios and its subsidiary Carbiolice, which aim to launch degradable bioplastics with limited lifespan for the packaging industry by 2020. more ➔
Biomarker predicts response to TNF blockersA new assay that accurately measures how arthritis patients respond to treatment with TNFalpha blockers such as adalimumab, open up the way to predict efficacy. more ➔
UK launches new payment model for antimicrobialsIn order to incentivise drug companies to re-enter development of antibiotics, the UK government announced it will establish a licence model to assure developers sufficient return on investments (RO … more ➔
BioNtech swallows MAB Discovery antibody unitImmunoncology and vaccine specialist BioNTech AG is broadening its antibody discovery capabilities by acquiring MAB Discovery’s antibody generation unit. more ➔
